Brokerages Set Ocular Therapeutix, Inc. (NASDAQ:OCUL) PT at $15.67

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $15.67.

Several analysts have issued reports on the company. Robert W. Baird dropped their target price on Ocular Therapeutix from $18.00 to $17.00 and set an "outperform" rating for the company in a report on Thursday, August 8th. Piper Sandler reissued an "overweight" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a report on Friday, June 21st. HC Wainwright reaffirmed a "buy" rating and set a $14.00 target price on shares of Ocular Therapeutix in a research note on Thursday, August 1st. Finally, TD Cowen cut shares of Ocular Therapeutix from a "strong-buy" rating to a "hold" rating in a research note on Friday, June 21st.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Atlas Capital Advisors LLC acquired a new position in shares of Ocular Therapeutix in the 2nd quarter worth approximately $34,000. Amalgamated Bank boosted its position in shares of Ocular Therapeutix by 37.9% during the second quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company's stock worth $37,000 after buying an additional 1,481 shares during the period. Trust Co. of Vermont boosted its position in shares of Ocular Therapeutix by 20.0% during the fourth quarter. Trust Co. of Vermont now owns 6,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 1,000 shares during the period. Algert Global LLC acquired a new stake in shares of Ocular Therapeutix in the second quarter valued at $69,000. Finally, Bayesian Capital Management LP purchased a new stake in shares of Ocular Therapeutix in the 1st quarter valued at $94,000. Hedge funds and other institutional investors own 59.21% of the company's stock.

Ocular Therapeutix Price Performance

Shares of NASDAQ OCUL traded down $0.16 during mid-day trading on Tuesday, reaching $9.32. The company's stock had a trading volume of 783,146 shares, compared to its average volume of 1,955,513. The stock has a market capitalization of $1.44 billion, a P/E ratio of -6.90 and a beta of 1.29. Ocular Therapeutix has a 1-year low of $2.00 and a 1-year high of $11.31. The stock has a 50-day moving average of $8.65 and a two-hundred day moving average of $7.36. The company has a debt-to-equity ratio of 0.18, a quick ratio of 16.55 and a current ratio of 16.64.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.04). The business had revenue of $16.40 million during the quarter, compared to analysts' expectations of $15.85 million. Ocular Therapeutix had a negative return on equity of 52.75% and a negative net margin of 226.46%. The company's revenue for the quarter was up 7.9% compared to the same quarter last year. During the same period last year, the business earned ($0.27) earnings per share. On average, equities research analysts anticipate that Ocular Therapeutix will post -1.02 EPS for the current fiscal year.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.